BioMarin Pharmaceuticals BMRN KUVAN — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's kuvan — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's KUVAN — total revenues?
- BioMarin Pharmaceuticals (BMRN) reported KUVAN — total revenues of $23.88M in Q1 2026.
- How has BioMarin Pharmaceuticals's KUVAN — total revenues changed year-over-year?
- BioMarin Pharmaceuticals's KUVAN — total revenues decreased by 5.0% year-over-year, from $25.14M to $23.88M.
- What is the long-term trend for BioMarin Pharmaceuticals's KUVAN — total revenues?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's KUVAN — total revenues has grown at a -23.2% compound annual growth rate (CAGR), from $285.78M to $99.53M.
- What does KUVAN — total revenues mean?
- The total sales revenue generated by the Kuvan product line.
- How do you interpret KUVAN — total revenues?
- An increase indicates strong market demand or successful pricing strategies for the product, while a decrease suggests potential loss of market share to generics or declining patient adoption.
- How does KUVAN — total revenues compare across companies?
- Comparable to specific product-level revenue disclosures in the rare disease or specialty pharmaceutical sectors.